Shattuck Labs Inc (STTK) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Shattuck Labs Inc stock $2.50, price $4.66, that is 46.4% below the price, quality 38 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Shattuck Labs Inc
STTK · USFar too expensive (fair value 46% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $0.7320 – $21.60 · fair‑value band $1.88 – $3.13 · the $4.66 price screens above the $2.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Shattuck Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Show moreShow less
The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.
The company was incorporated in 2016 and is headquartered in Austin, Texas.
Stock analysis
Shattuck Labs Inc (STTK) currently trades at $4.66, while our estimate is $2.50, 46% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.88 (bear) to $3.13 (bull), the price of $4.66 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Shattuck Labs Inc reported revenue of $1.0M in FY2025 versus $30.0M in FY2021, a compound −57.3%/yr. Reported net income was −$48.8M in FY2025.
Key figures
Market cap $605M Small · EPS (TTM) $−0.4700 · Return on equity −39.2% · Return on assets (EBIT) −53.6% (5-year average) · Operating margin −5,571% · Revenue (TTM) $1.0M · Revenue growth (YoY) −66.6% · Free cash flow −$40.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 141% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −46%, STTK screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $250,000, on Jun 9, 2026. Over the same period, 2 people sold shares worth $379,305.
- SaleAbhinav A. ShuklaChief Technical Officer3× since May 12, 2026: 25,907 shares, avg. $7.07$183,250Jul 2, 202610b5-1 plan
- SaleArundathy N. PanditeChief Medical Officer2× since May 12, 2026: 60,000 shares, avg. $6.81$408,600Jun 30, 202610b5-1 plan
- BuyClay B SiegallDirector62,500 shares at $4.00$250,000Jun 9, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Shattuck Labs Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs STTK |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs STTK |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs STTK |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs STTK |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs STTK |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs STTK |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs STTK |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs STTK |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs STTK |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs STTK |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shattuck Labs Inc (STTK) overvalued or undervalued?
What is the fair value of STTK?
What is the quality score of STTK?
What is the price target for Shattuck Labs Inc (STTK)?
What is the Shattuck Labs Inc stock forecast for 2026?
What is the revenue of Shattuck Labs Inc (STTK)?
What is the intrinsic value of Shattuck Labs Inc (STTK)?
Is Shattuck Labs Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of STTK?
How much is Shattuck Labs Inc worth?
What do the bullish and bearish scenarios say about STTK?
How solid is the balance sheet of Shattuck Labs Inc (STTK)?
How far is STTK from its 52-week high?
Which stocks are comparable to Shattuck Labs Inc?
Is Shattuck Labs Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Shattuck Labs Inc (STTK)?
What should I pay attention to with Shattuck Labs Inc right now?
Key figures of Shattuck Labs Inc
How large is the market capitalisation of Shattuck Labs Inc (STTK)?
What are the earnings per share of Shattuck Labs Inc (STTK)?
What is the return on equity of Shattuck Labs Inc (STTK)?
What is the EBIT return on assets of Shattuck Labs Inc (STTK)?
What is the operating margin of Shattuck Labs Inc (STTK)?
How fast is revenue growing at Shattuck Labs Inc (STTK)?
How much free cash flow does Shattuck Labs Inc (STTK) generate?
How much net cash does Shattuck Labs Inc (STTK) hold?
Watch Shattuck Labs Inc in the live analysis
One click puts Shattuck Labs Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.